Upfront investment burden for new medical-related businesses

「In Healthcare as well, the business as a whole reported lower revenue and profit because the impact of tariffs and increased provisions for certain transactions put pressure on profit.」

「 営 業 利 益 13 67 3 15 0 60」

「In Healthcare, the Life Science Solutions field was affected by stagnant market conditions in the Americas. In addition, both the Life Science Solutions and Eye Care Solutions fields were affected by tariffs, resulting in lower revenue and profit for the business as a whole.」

「In Healthcare, the Life Science Solutions and Eye Care Solutions fields were affected by stagnant market conditions, but the benefit of the weaker yen resulted in higher revenue overall. However, profit declined overall due to higher costs caused by rising prices and the impact of investments for the future.」

「In addition to higher costs caused by rising prices, profit declined overall due to the impact of provisions recognized in the second-quarter consolidated accounting period concerning an overseas subsidiary in the Eye Care Solutions field and related expenses.」

「In Healthcare, although the business was affected by shortages of some electronic components and other items, firm sales in the Life Science Solutions field and the benefit of the weaker yen resulted in higher revenue overall. However, profit declined overall due to higher costs caused by rising prices, the disposal and valuation losses of inventories, and the impact of provisions recognized in the second-quarter consolidated accounting period and related investigation expenses concerning an overseas subsidiary in the Eye Care Solutions field.」

「In the Healthcare Business, in the Life Science Solutions and Eye Care Solutions fields, some effects of tight supply and demand for electronic components and other items remained. However, strong orders, carried-over shipments from the previous fiscal year and the benefit of a weaker yen resulted in higher revenue and higher profit for the business as a whole.」

「As a result, revenue from this business was ¥9,939.4 million, up 35.7% from the previous fiscal year, and operating profit was ¥1,158.2 million, up 164.1% from the previous fiscal year.」

「In the Life Science Solutions and Eye Care Solutions fields of Healthcare, strong orders and the benefit of the weaker yen resulted in substantial increases in revenue and profit for the business as a whole compared with the same period of the previous year.」

「As a result, revenue from this business was ¥4,666.8 million, up 41.2% year on year, and operating profit was ¥367.3 million, up 291.2% year on year.」

「In the Healthcare Business, production in the Life Science Solutions and Eye Care Solutions fields continued to be affected by tight supply and demand for electronic components, including semiconductors. However, efforts to minimize the impact, together with strong orders, resulted in higher revenue and higher profit for the business as a whole compared with the same period of the previous year.」

「As a result, revenue from this business was ¥7,324.3 million, up 16.5% from the previous fiscal year, and operating profit was ¥438.5 million, compared with an operating loss of ¥3,091 million in the previous fiscal year, marking a return to profitability.」

「In Healthcare, the recovery trend from the impact of COVID-19 continued, resulting in substantial increases in revenue and profit in the Life Science Solutions and Eye Care Solutions fields.」

「As a result, revenue from this business was ¥3,305.7 million, up 28.6% year on year, and operating profit was ¥939 million, compared with an operating loss of ¥2,358 million in the same period of the previous year.」

「In Healthcare, market conditions recovered from the impact of the spread of COVID-19 in the same period of the previous year in the Life Science Solutions and Eye Care Solutions fields, resulting in higher revenue and profit for the business as a whole.」

「As a result, revenue from this business was ¥6,284.8 million, up 1.3% from the previous fiscal year. Profitability improved in all fields, but an operating loss of ¥3,091 million was recorded due to the recognition of impairment losses on fixed assets, compared with an operating loss of ¥2,455 million in the previous fiscal year.」

「In Healthcare, revenue and profit increased in the consolidated third-quarter accounting period as the Bioscience field remained firm and the Ophthalmic Diagnostics field performed well from October onward. During the cumulative consolidated third-quarter period, revenue declined significantly due to the substantial impact of the spread of COVID-19 in the first half, but the loss remained at approximately the same level as in the same period of the previous year.」

「As a result, revenue from this business was ¥2,571.1 million, down 14.6% year on year, and the operating loss was ¥2,358 million, compared with an operating loss of ¥1,223 million in the same period of the previous year.」

「As a result, overall business revenue declined, and although efforts were made to control expenses, the loss widened.」

「As a result, revenue from this business declined 5.2% from the previous fiscal year to ¥6,202.4 million. Despite efforts to minimize the loss through expense controls and other measures, the loss widened, and the operating loss was ¥2,455 million, compared with an operating loss of ¥1,937 million in the previous fiscal year.」

「In Healthcare, the Bioscience field generated lower revenue as sales of biological microscopes declined. The Ophthalmic Diagnostics field generated higher revenue as sales of ultra-widefield scanning laser ophthalmoscopes remained firm. As a result, overall business revenue increased, and the loss narrowed partly because of a more focused investment strategy and other measures.」

「As a result, revenue from this business was ¥3,009.3 million, up 2.3% year on year, while the operating loss narrowed to ¥1,223 million through a more focused investment strategy and other measures, compared with an operating loss of ¥2,374 million in the same period of the previous year.」

「As a result, total business revenue declined, but the deficit narrowed through improvements in the cost structure of biological microscopes and the narrowing of investment priorities.」

「Overall, strategic investment in ophthalmic diagnostics and regenerative medicine was carried out as planned, while profitability improved through fixed-cost reductions and other measures. As a result, revenue from this business was ¥6,543.4 million, up 15.2% from the previous fiscal year, and the operating loss was ¥1,937 million, compared with an operating loss of ¥3,263 million in the previous fiscal year.」

「In the Healthcare business, the Bioscience field generated higher revenue as sales of biological microscopes increased, mainly overseas, while the Ophthalmic Diagnostics field also generated higher revenue as sales of ultra-widefield scanning laser ophthalmoscopes increased. As a result, overall business revenue increased, but the operating loss continued because strategic investment in ophthalmic diagnostics and regenerative medicine was made as planned.」

「As a result, revenue from this business was ¥2,940.3 million, up 16.3% year on year, but an operating loss of ¥2,374 million was recorded, compared with an operating loss of ¥2,179 million in the same period of the previous year, due to increased strategic investment in ophthalmic diagnostics, regenerative medicine and other areas.」

「As a result, overall business revenue increased, and the operating loss was kept at approximately the same level as in the previous year despite increased upfront investment in new businesses.」

「As a result, revenue from this business was ¥5,681.8 million, up 1.8% year on year, while the operating loss was ¥3,263 million, compared with an operating loss of ¥660 million in the previous fiscal year.」

「In the Healthcare business, sales in the bioscience field remained at approximately the same level as in the same period of the previous year, due to delays in the execution of government budgets overseas. In the ophthalmic diagnostics field, sales of ultra-widefield scanning laser ophthalmoscopes remained firm, particularly in Europe and the United States, resulting in higher revenue. Consequently, although revenue increased for the business as a whole, the loss widened due to the impact of upfront investment and other factors related to new businesses.」

「As a result, revenue from the business was ¥25,285 million, up 5.0% year on year, but it recorded an operating loss of ¥2,179 million due to the impact of upfront investment and other factors related to new businesses, compared with an operating loss of ¥692 million in the same period of the previous year.」

「The Medical business recorded higher revenue as sales of retinal imaging diagnostic equipment remained firm, particularly in North America, but recorded an operating loss due to the impact of upfront investment and other factors related to new businesses.」

「As a result, revenue from the business was ¥20,276 million, but it recorded an operating loss of ¥1,599 million due to the impact of upfront investment and other factors related to new medical businesses.」

「As a result, revenue from the business was ¥9,012 million, but it recorded an operating loss of ¥2,438 million due to the impact of upfront investment and other factors related to new medical businesses.」

「Medical business segment profit or loss (△): △¥1,445 million」

「The company reported an operating loss of ¥4,675 million due to the impact of upfront investment and other factors related to new medical businesses.」